Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de eficácia e segurança de nipocalimabe para adultos com polineuropatia desmielinizante inflamatória crônica (PDIC)

2 de novembro de 2026 atualizado por: Janssen Research & Development, LLC

Fase 2/3, Multiestágio, Multicêntrico, Randomizado, Duplo-cego, Estudo de Retirada de Grupo Paralelo Controlado por Placebo para Avaliar a Eficácia e Segurança do Nipocalimabe Administrado a Adultos com Polineuropatia Desmielinizante Inflamatória Crônica (PDIC)

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

201

Estágio

  • Fase 2
  • Fase 3

Acesso expandido

Temporariamente indisponível fora do ensaio clínico. Consulte registro de acesso expandido.

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Berlin, Alemanha, 13347
        • Ativo, não recrutando
        • Judisches Krankenhaus Berlin
      • Bochum, Alemanha, 44791
        • Concluído
        • St. Josef-Hospital, Ruhr-Universität Bochum
      • Halle, Alemanha, 6120
        • Ativo, não recrutando
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Hanover, Alemanha, 30625
        • Ativo, não recrutando
        • Medizinische Hochschule Hannover
      • Leipzig, Alemanha, 4103
        • Concluído
        • Universitaetsklinikum Leipzig
      • Potsdam, Alemanha, 14471
        • Concluído
        • St Josefs Krankenhaus Potsdam Sanssouci
      • Buenos Aires, Argentina, C1199ABB
        • Ativo, não recrutando
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, C1428AQK
        • Recrutamento
        • Instituto Fleni
      • Buenos Aires, Argentina, C1428
        • Concluído
        • Hospital Gral Agudos Ignacio Pirovano
      • Rosario, Argentina, 2900
        • Recrutamento
        • INECO Neurociencias Orono
      • Melbourne, Austrália, 3004
        • Concluído
        • The Alfred Hospital
      • Parkwood, Austrália, 4215
        • Concluído
        • Gold Coast University Hospital
      • Ottawa, Canadá, K1N 6N5
        • Recrutamento
        • The Ottawa Hospital Ottawa NeuroMuscular Centre
      • Beijing, China, 100191
        • Concluído
        • Peking University Third Hospital
      • Beijing, China, 100034
        • Concluído
        • Peking University First Hospital
      • Beijing, China, 100053
        • Ativo, não recrutando
        • Xuanwu Hospital ,Capital Medical University
      • Beijing, China, 100070
        • Ativo, não recrutando
        • Beijing Tiantan Hospital, Capital Medical University
      • Changchun, China, 130021
        • Ativo, não recrutando
        • The First Hospital of Jilin University
      • Changsha, China, 410008
        • Concluído
        • Xiangya Hospital Central South University
      • Changsha, China, 410008
        • Ativo, não recrutando
        • The Third Xiangya Hospital of Central Sourth University
      • Chengdu, China, 610072
        • Concluído
        • Sichuan Provincial Peoples Hospital
      • Chifeng, China, 024000
        • Concluído
        • Chifeng Municipal Hospital
      • Fuzhou, China, 350001
        • Ativo, não recrutando
        • Fujian Medical University Union Hospital
      • Guangzhou, China, 510080
        • Ativo, não recrutando
        • The First Affiliated Hospital Sun Yat sen University
      • Jinan, China, 250012
        • Ativo, não recrutando
        • Qilu Hospital of Shandong University
      • Jinan, China, 250014
        • Concluído
        • Qianfoshan hospital of Shandong Province
      • Nanchang, China, 330006
        • Ativo, não recrutando
        • The First Affiliated Hospital of NanChang University
      • Shanghai, China, 200336
        • Concluído
        • Tong Ren Hospital Shanghai Jiao Tong University school of medicine
      • Shanghai, China, 200040
        • Ativo, não recrutando
        • Huashan Hospital Fudan University
      • Wuhan, China, 430023
        • Concluído
        • Renmin Hospital of Wuhan University
      • Xi'an, China, 710032
        • Concluído
        • Tangdu hospital the Fourth Military Medical
      • Xi'an, China, 710075
        • Ativo, não recrutando
        • Xi 'an GaoXin Hospital
      • Floridablanca, Colômbia, 681004
        • Concluído
        • Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
      • Medellín, Colômbia, 50021
        • Ativo, não recrutando
        • Instituto Neurológico de Colombia
      • Seoul, Coréia do Sul, 05030
        • Concluído
        • Konkuk University Medical Center
      • Seoul, Coréia do Sul, 02447
        • Concluído
        • Kyunghee University Medical Center
      • Seoul, Coréia do Sul, 135-710
        • Concluído
        • Samsung Medical Center
      • Alicante, Espanha, 03010
        • Ativo, não recrutando
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, Espanha, 8035
        • Concluído
        • Hosp Univ Vall D Hebron
      • Bilbao, Espanha, 48013
        • Ativo, não recrutando
        • Hosp. Univ. de Basurto
      • Donostia / San Sebastian, Espanha, 20014
        • Concluído
        • Hosp. Univ. Donostia
      • Madrid, Espanha, 28040
        • Concluído
        • Hosp. Clinico San Carlos
      • Seville, Espanha, 41009
        • Ativo, não recrutando
        • Hosp. Virgen Macarena
    • Colorado
      • Centennial, Colorado, Estados Unidos, 80112
        • Ativo, não recrutando
        • IMMUNOe Health and Research Centers
    • Florida
      • Coral Springs, Florida, Estados Unidos, 33067
        • Concluído
        • Healthcare Innovations Institute Inc
      • Maitland, Florida, Estados Unidos, 32751
        • Concluído
        • Neurology Associates PA
      • Miami, Florida, Estados Unidos, 33136
        • Ativo, não recrutando
        • ALS Center at the University of Miami
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30912
        • Concluído
        • Augusta University
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Concluído
        • University of Kansas Medical Center
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Concluído
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02111
        • Concluído
        • Boston Clinical Trials
    • Michigan
      • Royal Oak, Michigan, Estados Unidos, 48073
        • Concluído
        • Beaumont Hospital Royal Oak
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64128
        • Concluído
        • Kansas City Veterans Affairs Medical Center
    • New York
      • New York, New York, Estados Unidos, 10032
        • Concluído
        • The Neurological Institute of New York
      • Patchogue, New York, Estados Unidos, 11772
        • Concluído
        • South Shore Neurologic Associates - Patchogue
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Concluído
        • The Neurological Institute, PA
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Ativo, não recrutando
        • Cleveland Clinic Main Campus
    • Texas
      • Austin, Texas, Estados Unidos, 78756
        • Concluído
        • Austin Neuromuscular Center
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Ativo, não recrutando
        • Advocate Health - Aurora St. Luke's Medical Center
      • Bordeaux, França, 33000
        • Concluído
        • CHU Bordeaux
      • Bron, França, 69699
        • Concluído
        • Hospices Civils de Lyon HCL
      • Le Kremlin-Bicêtre, França, 94270
        • Ativo, não recrutando
        • Hopital de Bicetre
      • Marseille, França, 13385
        • Ativo, não recrutando
        • Hopital de la Timone
      • Nice, França, 06000
        • Ativo, não recrutando
        • Hopital PASTEUR
      • Nîmes, França, 30029
        • Ativo, não recrutando
        • CHU Nimes Hopital Caremeau
      • Paris, França, 75013
        • Concluído
        • Hopital de la Pitie Salpetriere
      • Paris, França, 75019
        • Concluído
        • Fondation Adolphe de Rothschild Hospital
      • Strasbourg, França, 67200
        • Ativo, não recrutando
        • CHRU Strasbourg
      • Athens, Grécia, 12462
        • Recrutamento
        • Attikon General Hospital of Athens
      • Athens, Grécia, 11527
        • Concluído
        • Papageorgiou General Hospital Of Thessaloniki
      • Pátrai, Grécia, 26504
        • Concluído
        • Patras University Hospital
      • Thessaloniki, Grécia, 54636
        • Recrutamento
        • Ahepa Hospital Aristotle University of Thessaloniki
      • Catania, Itália, 95123
        • Concluído
        • Azienda Ospedaliero-Universitaria Policlinico di Catania
      • Genova, Itália, 16132
        • Concluído
        • Azienda Ospedaliera Universitaria San Martino di Genova
      • Milan, Itália, 20144
        • Concluído
        • Casa di Cura del Policlinico
      • Milan, Itália, 20133
        • Concluído
        • Istituto Neurologico Carlo Besta
      • Naples, Itália, 80131
        • Ativo, não recrutando
        • Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
      • Orbassano, Itália, 10043
        • Concluído
        • Aou San Luigi Gonzaga
      • Pavia, Itália, 27100
        • Concluído
        • Fondazione Istituto Neurologico Casimiro Mondino
      • Roma, Itália, 00168
        • Concluído
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Rozzano, Itália, 20086
        • Concluído
        • IRCCS Istituto Clinico Humanitas
      • Asahikawa, Japão, 070-0901
        • Ativo, não recrutando
        • National Hospital Organization Asahikawa Medical Center
      • Bunkyō City, Japão, 113 8519
        • Ativo, não recrutando
        • Institute of Science Tokyo Hospital
      • Chiba, Japão, 260-8677
        • Concluído
        • Chiba University Hospital
      • Hamamatsu, Japão, 430-8558
        • Ativo, não recrutando
        • Seirei Hamamatsu General Hospital
      • Isehara, Japão, 259-1193
        • Ativo, não recrutando
        • Tokai University Hospital
      • Kobe, Japão, 650 0047
        • Concluído
        • Kobe City Medical Center General Hospital
      • Kodaira-shi, Japão, 187-8551
        • Ativo, não recrutando
        • National Center of Neurology and Psychiatry
      • Koshigaya, Japão, 343-8555
        • Ativo, não recrutando
        • Saitama Medical Center
      • Kumamoto, Japão, 860-8556
        • Concluído
        • Kumamoto University Hospital
      • Nagoya, Japão, 466-8560
        • Ativo, não recrutando
        • Nagoya University Hospital
      • Nagoya, Japão, 455-8530
        • Ativo, não recrutando
        • Chubu Rosai Hospital
      • Osaka Sayama Shi, Japão, 589 8511
        • Concluído
        • Kindai University Hospital
      • Sendai, Japão, 983-8520
        • Ativo, não recrutando
        • National Hospital Organization Sendai Medical Center
      • Shimotsuga Gun, Japão, 321 0293
        • Concluído
        • Dokkyo Medical University Hospital
      • Shinjuku-ku, Japão, 162-8666
        • Concluído
        • Tokyo Women's Medical University Hospital
      • Tenri, Japão, 632-0015
        • Concluído
        • Tenri Hospital
      • Toon-shi, Japão, 791-0295
        • Concluído
        • Ehime University Hospital
      • Toyama, Japão, 930-0194
        • Concluído
        • Toyama University Hospital
      • Ube, Japão, 755-8505
        • Concluído
        • Yamaguchi University Hospital
      • Monterrey, México, 64710
        • Concluído
        • i Can Oncology Center
      • Tlalnepantla, México, 54055
        • Recrutamento
        • Clinical Research Institute S.C.
      • Chorzów, Polônia, 41 500
        • Concluído
        • Centrum Medyczne
      • Krakow, Polônia, 30 539
        • Concluído
        • Specjalistyczne Gabinety Lekarskie
      • Lublin, Polônia, 20 093
        • Concluído
        • Prywatny Gabinet Lekarski
      • Poznan, Polônia, 61 731
        • Ativo, não recrutando
        • Clinical Research Center sp z o o MEDIC R s k
      • Almada, Portugal, 2805-267
        • Ativo, não recrutando
        • Hospital Garcia de Orta
      • Braga, Portugal, 4710-243
        • Concluído
        • Hospital de Braga
      • Porto, Portugal, 4200 319
        • Ativo, não recrutando
        • Centro Hospitalar de Sao Joao Epe
      • Birmingham, Reino Unido, B15 2TH
        • Concluído
        • University Hospitals Birmingham NHS Foundation Trust
      • Devon, Reino Unido, EX2 5DW
        • Concluído
        • Royal Devon & Exeter Hospital
      • Glasgow, Reino Unido, G514TF
        • Ativo, não recrutando
        • NHS Greater Glasgow and Clyde
      • London, Reino Unido, NW3 2QG
        • Concluído
        • Royal Free Hospital
      • Sheffield, Reino Unido, S10 2 JF
        • Ativo, não recrutando
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Kaohsiung City, Taiwan, 88301
        • Concluído
        • Kaohsiung Chang Gung Memorial Hospital
      • Taipei, Taiwan, 100
        • Ativo, não recrutando
        • National Taiwan University Hospital
      • Taipei, Taiwan, 111
        • Ativo, não recrutando
        • Shin Kong Wu Ho Su Memorial Hospital
      • Hradec Králové, Tcheca, 500 05
        • Ativo, não recrutando
        • Fakultni nemocnice Hradec Kralove
      • Ostrava, Tcheca, 708 52
        • Concluído
        • Fakultni Nemocnice Ostrava
      • Pardubice, Tcheca, 53203
        • Concluído
        • Pardubicka krajska nemocnice a s

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
  • Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
  • Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
  • Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
  • Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
  • Other protocol-defined inclusion criteria will apply

Exclusion Criteria:

  • Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
  • Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
  • Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
  • Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
  • Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
  • Other protocol-defined exclusion criteria will apply

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Nipocalimab

Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Nipocalimab will be administered intravenously.

Outros nomes:
  • JNJ-80202135
  • M281
Comparador de Placebo: Placebo

Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Placebo will be administered intravenously.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Stage B: Time to First Occurrence of a Relapse Event
Prazo: Up to 52 weeks

Stage B time to first occurrence of a relapse event will be reported.

Up to 52 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Prazo: 12 weeks

Time to initial confirmed ECI will be reported.

12 weeks
Stage A: Percentage of Responders as Determined by ECI
Prazo: 12 weeks

Stage A percentage of responders as determined by ECI will be reported.

12 weeks
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Prazo: Baseline to 12 weeks

Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability.

Baseline to 12 weeks
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Prazo: Baseline to 12 weeks

Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Prazo: Baseline to 12 weeks

Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Prazo: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Prazo: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Prazo: Up to 52 weeks

Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Prazo: Up to 52 weeks

Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Prazo: Up to 52 weeks

Change from Stage B baseline over time in adjusted INCAT disability score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Prazo: Up to 52 weeks

Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Prazo: Up to 52 weeks

Change from Stage B baseline over time in I-RODS centile score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Prazo: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Prazo: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Prazo: Up to 52 weeks

Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported.

Up to 52 weeks
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Serious Adverse Events (SAEs)
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in ECG values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Vital Signs Values Over Time
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in vital signs values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Clinical Laboratory Values Over Time
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in clinical laboratory values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant ECG Abnormalities
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant ECG abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Vital Signs Abnormalities
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant vital signs abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant clinical laboratory abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with ADA to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Titers of ADA to Nipocalimab
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Titers of ADA to nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Prazo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with NAb to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Prazo: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Change from baseline in total serum IgG concentrations levels over time will be reported.

Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

23 de setembro de 2022

Conclusão Primária (Estimado)

15 de dezembro de 2026

Conclusão do estudo (Estimado)

11 de julho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

7 de abril de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

7 de abril de 2022

Primeira postagem (Real)

14 de abril de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CR109195
  • 80202135CDP3001 (Outro identificador: Janssen Research & Development, LLC)
  • 2021-003234-37 (Número EudraCT)
  • 2023-508425-28-00 (Identificador de registro: EUCT number)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever